Download PDF Roscoff, France, October 1, 2025 – SeaBeLife, a biotechnology company developing innovative drug candidates intended to block cellular … Lire la suite
download PDF SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues … Lire la suite
Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute … Lire la suite
SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death. Roscoff, May 17th, 2021. SeaBeLife, … Lire la suite
SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death. Roscoff, June 15, 2020. SeaBeLife, a pharmaceutical … Lire la suite
